Oncology and Therapy最新文献

{"title":"IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment.","authors":"Sridevi Rajeeve, Saurabh P Nagar, Sabyasachi Ghosh, Victoria Alegria, Justin Hayne, Bruno Emond, Jessica Maitland, Zaina P Qureshi, Larry D Anderson","doi":"10.1007/s40487-026-00455-6","DOIUrl":"10.1007/s40487-026-00455-6","url":null,"abstract":"<p><strong>Introduction: </strong>Ciltacabtagene autoleucel (cilta-cel) has demonstrated deep and durable responses in patients with relapsed/refractory multiple myeloma (RRMM), supporting the goal of sustained minimal residual disease (MRD) negativity as a marker for potential functional cure, characterized by prolonged treatment-free disease control. Initially, cilta-cel was approved in the US for RRMM after ≥ 4 prior lines of therapy (LOT), and after 1-3 prior LOT in April 2024. This study describes real-world clinical outcomes, including MRD negativity, of cilta-cel after 1-3 prior LOT.</p><p><strong>Methods: </strong>Electronic medical records from Loopback Analytics (April 2024-May 2025) were used, supplemented with physician notes. Adults with RRMM treated with cilta-cel after 1-3 prior LOT were included. Post-infusion outcomes (cilta-cel response, MRD negativity, disease progression, and overall survival) were assessed overall and by bridging therapy (BT) regimen.</p><p><strong>Results: </strong>Overall, 120 patients were included (median age 67 years, 43.3% female). Prior to infusion, 87.5% received BT, including alkylator-based (28.6%), IMiD ± mAb-based (25.7%), PI-based (20.0%), talquetamab (14.3%), and other regimens (11.4%). Over a median follow-up of 5.8 months, among patients with a response assessment (81.7%), the overall response rate (ORR) to cilta-cel was 98.0%, including 72.4% with complete response. Among 36 MRD-evaluable patients, MRD negativity (10^-5) was achieved in 35 (97.2%), with a median time to MRD negativity of 80.0 days. At last follow-up, 94.2% of patients remained progression-free, 95.8% had not initiated subsequent treatment, and 99.2% remained alive. Across BT regimens, ORR to cilta-cel was 95-100% and MRD negativity was achieved in 80-100%.</p><p><strong>Conclusions: </strong>This real-world study demonstrates the effectiveness of cilta-cel in RRMM after 1-3 prior LOT. High rates of response and MRD negativity were reported overall and across BT regimens, including talquetamab. Longer follow-up with repeated MRD measurements may provide further insights into response durability and survival outcomes, helping to contextualize the potential for a functional cure.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"1025-1041"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148340639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Actionability Analysis of Comprehensive Genomic Profiling Versus Single/Small-Gene Panels.","authors":"Paul Spin, Bela Bapat, Chad Moretz, Robert Dumanois, Adrienne M Gilligan, Mostafa Shokoohi, Emily Borgundvaag, John Fox, Carlo Bifulco, David Bartlett","doi":"10.1007/s40487-026-00453-8","DOIUrl":"10.1007/s40487-026-00453-8","url":null,"abstract":"<p><strong>Introduction: </strong>Comprehensive genomic profiling (CGP) enables identification of patients eligible for targeted treatments, making it essential in the management of advanced cancer. This retrospective real-world study compared actionable mutations in CGP-tested patients with advanced/metastatic solid tumors to those who received single-gene/small-panel (SP) tests.</p><p><strong>Methods: </strong>Patients aged > 18 years with advanced/metastatic solid tumors (including non-small cell lung cancer (NSCLC), colorectal cancer, prostate cancer, breast cancer, or melanoma) with a CGP or SP test reported between 1 January 2018, and 31 December 2022, were included. OncoKB-derived actionability was compared between the two cohorts. Inverse probability of treatment weighting (IPTW) was used to adjust for baseline characteristics. A weighted generalized linear model with log link was used to report actionability ratio (AR) and 95% confidence intervals (CI).</p><p><strong>Results: </strong>Among 406 patients (CGP-tested cohort: 202, SP-tested cohort: 204), approximately half were diagnosed with NSCLC. After adjusting for baseline characteristics, CGP testing detected more actionable alterations than SP: OncoKB level 1 (50.0% versus 31.4%; AR 1.76 [95% CI: 1.24, 2.51]; p = 0.002), OncoKB level 2 (22.8% versus 10.3%; AR 2.53 [95% CI: 1.17, 5.48]; p = 0.018), and OncoKB level 1 or level 2 or level R1 (55.9% versus 41.2%; AR 1.5 [95% CI: 1.11, 2.01]; p = 0.008).</p><p><strong>Conclusions: </strong>CGP testing identified more actionable genetic alterations compared with SP testing methods for patients with advanced/metastatic NSCLC, colorectal cancer, prostate cancer, breast cancer, or melanoma. Expanding reimbursement and coverage for CGP testing as well as expanding CGP use can facilitate equitable treatment access for patients with advanced/metastatic cancer.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"1011-1024"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148296745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gain and Loss of FLT3 Mutations in Patients with Acute Myeloid Leukemia: A Noninterventional Cohort Study (CLEVO).","authors":"Cristina Papayannidis, Irina Amitai, Pascal Turlure, Ann De Becker, Felix Mensah, Dina Elsouda, Ioanna Vardounioti, Jose Alejandro Palacios-Fabrega, Paresh Vyas, Blanca Boluda","doi":"10.1007/s40487-026-00427-w","DOIUrl":"10.1007/s40487-026-00427-w","url":null,"abstract":"<p><strong>Introduction: </strong>FMS-like tyrosine kinase 3 (FLT3) mutations show variable detectability in relapse/refractory acute myeloid leukemia (AML) with unclear clonal evolution dynamics.</p><p><strong>Methods: </strong>This prospective noninterventional study examined clonal evolution and outcomes from AML diagnosis to relapse/refractory disease occurrences.</p><p><strong>Results: </strong>Of 650 patients included, 172 were FLT3-positive (FLT3^pos) and 472 were FLT3-negative (FLT3^neg; 99.1% testing rate; unknown FLT3 status, six patients). At first occurrence, the FLT3 testing rate decreased (57.0% [166/291]). Among tested patients, 45 had FLT3^pos and 121 had FLT3^neg AML. A gain or loss of mutations was seen in 15.6% (7/45) of patients with FLT3^pos AML and 14.9% (18/121) of patients with FLT3^neg AML. Median (95% confidence interval [CI]) overall survival was 22.8 (19.6, not estimable [NE]) months across patients (FLT3^pos, NE;FLT3^neg, 20.3 [15.2-23.7] months; hazard ratio [HR] [95% CI] 0.6 [0.5-0.8]). Median (95% CI) disease-free survival across patients was NE (26.3-NE) (FLT3^pos, NE;FLT3^neg, NE; HR [95% CI] 0.8 [0.6-1.1]). Median event-free survival (95% CI) was 11.8 (10.0-15.5) months in all patients (FLT3^pos, 17.2 [11.0-NE] months;FLT3^neg, 10.4 [8.4-13.2] months; HR [95% CI] 0.8 [0.6-1.0]).</p><p><strong>Conclusions: </strong>Dynamic changes in FLT3 mutation status were observed during these patients' disease course. FLT3^pos status at baseline, but not at first occurrence, was associated with improved outcomes; other confounders should be considered. Timelier FLT3 mutation retesting may aid in personalizing treatment. Graphical abstract available for this article.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"655-670"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13304035/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147436262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Variants in Candidate Pharmacogenes with Response to Mercaptopurine and Methotrexate in Pediatric Acute Lymphoblastic Leukemia: A Single-Center Experience from Croatia.","authors":"Isidora Curic, Nikola Kotur, Bojan Ristivojevic, Djordje Pavlovic, Marina Jelovac, Katarina Krstajic, Mia Radosevic, Ana Djordjevic, Sonja Pavlovic, Jelena Roganovic, Branka Zukic","doi":"10.1007/s40487-026-00440-z","DOIUrl":"10.1007/s40487-026-00440-z","url":null,"abstract":"<p><strong>Introduction: </strong>Interindividual variability in the efficacy and toxicity of 6-mercaptopurine (6-MP) and methotrexate (MTX) drugs remains a major challenge in the treatment of pediatric acute lymphoblastic leukemia (ALL). Germline variation in pharmacogenes involved in drug metabolism, transport, and folate pathways may contribute to this variability.</p><p><strong>Methods: </strong>In this retrospective cohort study, 43 pediatric patients with ALL treated at a tertiary referral center in Croatia according to ALL IC-BFM 2002 or 2009 protocols were genotyped for eleven variants in TPMT, ITPA, NUDT15, PACSIN2, MTHFR, TYMS, SLC19A1, and SLCO1B1 genes. Associations with average 6-MP dose during maintenance therapy, MTX pharmacokinetics during consolidation and MTX-related toxicity were analyzed. A polygenic risk score (PRS) was constructed to assess cumulative genetic risk of developing toxicity when administering these two drugs.</p><p><strong>Results: </strong>Carriers of the ITPA rs1127354 variant required significantly lower average 6-MP doses compared with wild-type carriers. The NUDT15 rs61973267 variant was associated with higher tolerated 6-MP doses after exclusion of outliers. No significant associations were observed between individual variants and MTX clearance. A trend toward reduced risk of oral mucositis was observed in carriers of the SLCO1B1 rs4149056 variant. PRS analyses that included carriers of the TPMT rs1142345 and ITPA rs1127354 variants showed a borderline association with the requirement for 6-MP dose reduction.</p><p><strong>Conclusions: </strong>Our findings support a role for ITPA and NUDT15 variants in modulating 6-MP dose requirements, while single-variant associations with MTX pharmacokinetics and toxicity were limited and not supported. These results underscore the complexity of antimetabolite pharmacogenetics and suggest that integrative polygenic approaches may better capture clinically relevant pharmacogenetic risk.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"791-809"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13305058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147989416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiopharmaceutical Therapy in Oncology: Perspectives from Transatlantic Experts.","authors":"Désirée Deandreis, Heather Jacene, Patrick Therasse, Fabrice André, Fabrice Barlesi, Kevin Haigis, Karim Fizazi, Toni K Choueiri","doi":"10.1007/s40487-026-00432-z","DOIUrl":"10.1007/s40487-026-00432-z","url":null,"abstract":"<p><p>Radiopharmaceutical therapy (RPT), the administration of a radioactive element coupled with a targeting vector, is one of the most promising innovations in oncology, supported by clinical trials. A theranostic approach-the pairing of diagnostic and therapeutic RPTs sharing the same target-facilitates selective delivery of therapeutic radiation to cancer cells. Its advantages and limitations are determined by the molecular targeting mechanisms employed, as well as the types of ionising radiation emitted. Therefore, understanding the biology of cell-surface targets and molecular mechanisms governing target expression in cancers is critical to the development and clinical use of these agents. This review provides an overview of the latest advances in the application of targeted RPTs within oncology, as discussed at the Fourth Transatlantic Exchange in Oncology, a hybrid conference held in March 2025 that brought together experts from Dana-Farber Cancer Institute (Boston, MA, USA) and Gustave Roussy (Paris, France). Key topics included the targeting of prostate-specific membrane antigen (PSMA) for both imaging and therapy purposes in prostate cancer. In particular, PSMA-based imaging-encompassing both positron emission tomography (PET) and single-photon emission computed tomography (SPECT)-has become a fundamental tool for patient selection, evaluation of treatment response, and personalisation of therapeutic strategies. While theranostic approaches continue to pose challenges, they should increasingly enable improved treatment selection for patients with cancer, and more effective prediction of response and toxicity. Lessons learned from PSMA may apply to other emerging theranostic targets in prostate cancer and other tumour types, expanding the future potential of RPT applications. Beyond current achievements, new molecules and intensive translational research programs may optimise, potentiate and direct RPT. The impact of the expanding use of RPTs on healthcare systems was also addressed, defining strategies to overcome barriers and provide broader access to innovations in RPT in both clinical and research settings.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"499-518"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13303995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab: A Panel Chart Review Study.","authors":"Binod Dhakal, Moshe Y Levy, Gilbert Ko, Jinghua He, Nina Kim, Wenze Tang, Tonya Le Blanc, Jessica Fowler, Sarah Lucht, Madison Brown, Emily Bland, Camryn Craig, Sarah Giegerich, JaLyna Laney, Bruce Feinberg, Niodita Gupta-Werner, Shuchita Kaila, Peter Voorhees","doi":"10.1007/s40487-026-00429-8","DOIUrl":"10.1007/s40487-026-00429-8","url":null,"abstract":"<p><strong>Introduction: </strong>Teclistamab is an established standard of care for the treatment of relapsed/refractory multiple myeloma (RRMM) based on MajesTEC-1 study results. United States (US)-based real-world studies of teclistamab treatment have had limited follow-up, were conducted in academic settings and/or had small sample sizes. This real-world study was conducted in a primarily US community-based oncology provider network to assess the real-world effectiveness and safety profile of teclistamab.</p><p><strong>Methods: </strong>This retrospective, observational, cohort study used Cardinal Health's Oncology Provider Extended Network. Adult patients with RRMM who received teclistamab on or after 25 October 2022, were identified through medical chart review. Patient characteristics, treatment patterns, and treatment history were described. Clinical outcomes included adverse events, response and survival rates, and duration of response. Data are presented for all patients and US Prescribing Information (USPI)-aligned and unaligned subgroups.</p><p><strong>Results: </strong>The overall population included 101 patients, of which 30 and 71 were USPI-aligned and USPI-unaligned, respectively. Median age was 65.4 years, 86.1% had an Eastern Cooperative Oncology Group Performance Status score of 1 and 37.6% had a high-risk cytogenetic profile. Most patients were triple-class exposed (93.1%) and/or refractory (65.3%). Median follow-up was 13.8 months and overall response rates were 80.2%, 90.0%, and 76.1% in the overall, USPI-aligned, and USPI-unaligned subgroups, respectively. During step-up dosing, 32.7% and 8.9% of all patients had cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, respectively; 26.7% of all patients developed infections while receiving teclistamab.</p><p><strong>Conclusion: </strong>This real-world study demonstrated numerically higher response rates and broadly similar rates of adverse events in this population compared with the MajesTEC-1 trial, despite many patients having higher disease burden and worse performance status. These findings from primarily community oncology settings suggest that teclistamab is an effective treatment option for patients with RRMM in the real world.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"671-691"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13304050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Patient Perspectives on Upper Tract Urothelial Cancer: A Qualitative Interview Study.","authors":"Dina Filipenko, Michael Acquadro, Ola Ghatnekar, Carl Haakon Samuelsen, Ingolf Griebsch","doi":"10.1007/s40487-026-00423-0","DOIUrl":"10.1007/s40487-026-00423-0","url":null,"abstract":"<p><strong>Introduction: </strong>Patient interview data exploring the experiences of the most relevant symptoms and impacts of upper tract urothelial cancer (UTUC) remain scarce. This study aimed to develop a conceptual disease model (CDM) of UTUC grounded in patients' own experiences of UTUC and to capture disease-specific symptoms and impacts experienced before, during, and after cancer treatment.</p><p><strong>Methods: </strong>A targeted literature review (TLR) informed the qualitative interview guide development. Qualitative concept elicitation interviews were then performed with patients who had UTUC to understand their experiences of the disease and its treatment, focusing on symptoms and impacts. Interview transcripts were thematically analyzed using ATLAS.ti^©. The findings from both the TLR and qualitative interviews were synthesized to develop a CDM.</p><p><strong>Results: </strong>We interviewed 15 adults with UTUC (mean age, 56 years), including nine with low-grade and six with high-grade UTUC. Patients reported 22 symptoms: 11 pre-treatment and 21 during treatment and/or post-treatment. The most frequently reported pre-treatment symptoms were blood in urine (60%), fatigue/tiredness (53%), and pain (47%). During or post-treatment, the most frequently reported symptoms were fatigue/tiredness (93%), pain (47%), and weight loss (40%). Patients with low- and high-grade UTUC reported comparable numbers of distinct symptoms, both pre- and post-treatment. UTUC and its treatment impacted patients' emotional well-being (100%), activities of daily life (73%), relationships (73%), social functioning (60%), sleep (60%), and physical functioning (27%), and treatment burden was explicitly mentioned by 13%. The CDM of UTUC was developed, capturing the symptoms and impacts experienced by patients with low- or high-grade UTUC.</p><p><strong>Conclusions: </strong>This qualitative study identified a broad range of symptoms and impacts of UTUC and its treatment, highlighting the unmet patient needs associated with current UTUC management. Our findings provide a qualitative foundation to inform endpoint and clinical outcome assessment selections in clinical research and to guide patient-centered care strategies for UTUC.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"621-637"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13305077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147357390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases.","authors":"Surbhi Sidana, Saurabh P Nagar, Sabyasachi Ghosh, Lin Fan, Victoria Alegria, Kevin C De Braganca, Tamar Lengil, Mukta Sharma, Helen Pai, Matthew Perciavalle, Jessica Maitland, Bruno Emond, Todd Bixby, Zaina P Qureshi, Rafael Fonseca","doi":"10.1007/s40487-026-00433-y","DOIUrl":"10.1007/s40487-026-00433-y","url":null,"abstract":"<p><strong>Introduction: </strong>Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy approved in the USA for relapsed or refractory multiple myeloma (RRMM) as early as following first relapse, based on pivotal CARTITUDE-1 (≥ 4 prior lines of therapy [LOT]) and CARTITUDE-4 (1-3 prior LOT) trials, which reported high response rates and prolonged survival. In CARTITUDE-1 and CARTITUDE-4, rates of all-grade parkinsonism were 6% and < 1%, respectively, while rates of cranial nerve palsy were 3% and 9%, respectively. This study aimed to characterize new-onset nonimmune effector cell-associated neurotoxicity syndrome (non-ICANS) neurologic events (NEs) among patients with RRMM receiving cilta-cel after 1-3 or ≥ 4 prior LOT.</p><p><strong>Methods: </strong>This retrospective study used two real-world data sources: open and closed insurance claims from the Komodo Research Database (February 2021-November 2024), and electronic medical records from Loopback Analytics (February 2021-December 2024). New-onset non-ICANS NEs, including parkinsonism, cranial nerve palsy, and Guillain-Barré syndrome, were assessed from cilta-cel infusion until the end of clinical activity, death, or end of data availability. Analyses were conducted separately by database and stratified by LOT.</p><p><strong>Results: </strong>In patients with 1-3 prior LOT (Komodo: 124; Loopback: 79), over a median follow-up of 3.4-3.5 months, cranial nerve palsy occurred in 5.6% and 5.1% in Komodo and Loopback, respectively, with no parkinsonism or Guillain-Barré syndrome observed. In patients with ≥ 4 prior LOT (Komodo: 524; Loopback: 191), over a median follow-up of 13.2-13.3 months, parkinsonism occurred in 1.0% in both databases, cranial nerve palsy in 4.6% and 1.0%, and Guillain-Barré syndrome in 0.2% and 0.5% in Komodo and Loopback, respectively.</p><p><strong>Conclusions: </strong>In this real-world study, rates of non-ICANS NEs post-cilta-cel infusion across two databases were comparable to or lower than prior trials or real-world studies, reinforcing the favorable risk-benefit profile of cilta-cel in routine practice. Graphical Abstract available for this article.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"827-839"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13305209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147718573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of Disease, Treatment Patterns, and Healthcare Resource Utilization in Multiple Myeloma in the Middle East and North Africa Region: A Targeted Literature Review.","authors":"Meral Beksac, Mohamed Samra, Omar Abduljalil, Hasan Aal Yaseen, Sevgi Besisik, Guldane Cengi̇z Seval, Ashraf Elghandour, Gamal Fathy, Güner Hayri Özsan, Mahmoud Marashi, Ömür Gökmen Sevindik, Ruba Yaseen Ibrahim Taha, Bhumika Aggarwal, Jorge Mouro, Abhay Phansalkar","doi":"10.1007/s40487-026-00428-9","DOIUrl":"10.1007/s40487-026-00428-9","url":null,"abstract":"<p><p>Globally, the multiple myeloma (MM) landscape varies widely, with incidence, treatment patterns, outcomes, and healthcare resource utilization (HCRU) differing across countries and regions. Many factors contribute to these differences, including ethnicity, awareness, and socioeconomic influences. This is the first analysis aiming to explore factors associated with myeloma incidence and patient characteristics in the Middle East and North Africa (MENA) region. A literature search was conducted using PubMed and Embase from 1 January 2015 to 30 May 2025. Articles reporting outcomes of interest in patients with MM in the relevant MENA countries (Egypt, Saudi Arabia, Turkey, and the United Arab Emirates) were identified. Of 1400 articles identified in the search, 94 were included; four articles were added post hoc as gray literature. Most reported findings from retrospective observational studies (n = 66); more than half were conducted in Turkey. The age-standardized incidence rate in MENA was 1.49 per 100,000 people in 2019; median age at diagnosis was lower in the region (range 43-70 years) than that in global reports (70 years). Nearly half (49.7%) of all patients were treated with a regimen containing bortezomib; the second-most frequently used drug was lenalidomide in newly diagnosed MM and daratumumab in relapsed/refractory MM. Few patients (< 1%) were treated with quadruplet regimens. Overall response rates were generally high (35-90.2%), while survival outcomes varied (median progression-free and overall survival ranged from 2-97.7 months and 4-125.3 months, respectively). Adverse events were inconsistently reported across the studies; hematologic adverse events and peripheral neuropathy were commonly reported. HCRU data in the region were limited. We identified a paucity of comprehensive data on the epidemiology and management of MM in MENA. Improved understanding of treatment patterns and HCRU in the region may provide pathways to advancing access to newer therapies that can alleviate the disease and treatment burden of MM in MENA.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"449-498"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13304077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role and Characteristic of Multidisciplinarity in Hepatocellular Carcinoma Management and Care Pathway Certification: Bottom-Up Approach of the MDT Project in Italy.","authors":"Giuseppe Cabibbo, Caterina Cocuzza, Ciro Celsa, Maria Rosaria Attanasio, Antonio Avallone, Rossana Berardi, Roberto Bordonaro, Mariafiorella Brangi, Fabio Cartabellotta, Desiree Lucy Anna Rita Caudullo, Bruno Daniele, Giovan Giuseppe Di Costanzo, Piera Federico, Giovanni Galati, Salvatore Gruttadauria, Francesco Izzo, Anna Nappi, Giuseppina Pacella, Mauro Piccirillo, Ferdinando Riccardi, Laura Schiadà, Marta Schirripa, Marianna Silletta, Gianluca Svegliati Baroni, Emiliano Tamburini, Raffaella Tortora, Martina Assanti, Francesco Deligios, Giada Lodolo, Luca Pinto, Maurizio Russello","doi":"10.1007/s40487-026-00439-6","DOIUrl":"10.1007/s40487-026-00439-6","url":null,"abstract":"<p><strong>Introduction: </strong>Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, requiring a multidisciplinary approach for effective management. The MDT Project aimed to define and pilot a structured care model for HCC management in Italy, supported by the implementation of integrated care pathways (ICPs), to standardize organizational processes and ensure the organizational requirements needed for appropriate patient management.</p><p><strong>Methods: </strong>A multi-phase approach included a narrative review, semi-structured interviews with national experts, and the development of an optimal care model operationalized through a maturity model with 15 organizational elements. A total of 13 hospitals, selected to reflect national heterogeneity, participated in a pilot phase involving tailored action plans and hospital-specific ICPs. In total, ten hospitals proceeded to ICP implementation, and eight achieved certification by an external accreditation body. An expert consensus meeting subsequently validated the care model, key performance indicator (KPI) panel, and assessment tools. Organizational changes were assessed pre- and post intervention through the maturity model evaluation and a survey capturing clinicians' perceptions.</p><p><strong>Results: </strong>Organizational improvements were observed primarily in areas directly targeted by the action plans, including the formalization of care-flow processes, multidisciplinary team structuring, case management, and coordination processes. More limited progress was seen in information systems and KPI monitoring, which require structural investments. Clinicians perceived the certification process as helpful in consolidating procedural standardization and documentation quality.</p><p><strong>Conclusions: </strong>The MDT Project piloted an organizational model for HCC management in Italy, focusing on care-pathway governance, multidisciplinary coordination, and center readiness. These findings represent an initial step toward broader implementation; future phases should incorporate clinical outcomes and patient-reported measures to evaluate the model's long-term impact.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"767-789"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13303994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147983786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}